Articles published by BeiGene, Ltd.
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
April 26, 2024
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
April 23, 2024
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
March 06, 2024
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene to Present at Upcoming Investor Conferences
February 28, 2024
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 26, 2024
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
February 26, 2024
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
January 23, 2024
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
December 22, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
November 29, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
November 28, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
November 21, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
November 09, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene to Present at the Jefferies London Healthcare Conference
November 08, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
October 20, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
September 19, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
September 19, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
August 02, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.